{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:16Z","timestamp":1780963216692,"version":"3.54.1"},"reference-count":60,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinecjc.ca","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.cjca.2025.06.075","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T15:19:04Z","timestamp":1752592744000},"page":"S24-S32","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"S","title":["Integrating the Care of Metabolic Dysfunction\u2013associated Steatotic Liver Disease Into Cardiac Rehabilitation: A Multisystem Approach"],"prefix":"10.1016","volume":"41","author":[{"given":"Giada","family":"Sebastiani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Raggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Guaraldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2025.06.075_bib1","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jhep.2023.03.017","article-title":"Global burden of liver disease: 2023 update","volume":"79","author":"Devarbhavi","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.cjca.2025.06.075_bib2","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/s41395-018-0088-6","article-title":"NASH leading cause of liver transplant in women: updated analysis of indications for liver transplant and ethnic and gender variances","volume":"113","author":"Noureddin","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cjca.2025.06.075_bib3","doi-asserted-by":"crossref","first-page":"E429","DOI":"10.9778\/cmajo.20190212","article-title":"Burden of nonalcoholic fatty liver disease in Canada, 2019-2030: a modelling study","volume":"8","author":"Swain","year":"2020","journal-title":"CMAJ Open"},{"key":"10.1016\/j.cjca.2025.06.075_bib4","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.cjca.2025.06.075_bib5","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1016\/j.cgh.2024.03.006","article-title":"The global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among patients with type 2 diabetes","volume":"22","author":"Younossi","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cjca.2025.06.075_bib6","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1136\/gutjnl-2023-330110","article-title":"Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis","volume":"72","author":"En Li Cho","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.cjca.2025.06.075_bib7","doi-asserted-by":"crossref","first-page":"610","DOI":"10.7150\/ijbs.29599","article-title":"Obesity, nonalcoholic fatty liver disease and adipocytokines network in promotion of cancer","volume":"15","author":"Divella","year":"2019","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.cjca.2025.06.075_bib8","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.tem.2024.02.007","article-title":"Current status and future trends of the global burden of MASLD","volume":"35","author":"Miao","year":"2024","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.cjca.2025.06.075_bib9","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1161\/CIR.0000000000001123","article-title":"Heart disease and stroke statistics---2023 update: a report from the American Heart Association","volume":"147","author":"Tsao","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2025.06.075_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2022.909455","article-title":"The burden of liver cirrhosis in mortality: results from the global burden of disease study","volume":"10","author":"Ye","year":"2022","journal-title":"Front Public Health"},{"key":"10.1016\/j.cjca.2025.06.075_bib11","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/j.cgh.2015.08.015","article-title":"Current and future burden of chronic nonmalignant liver disease","volume":"13","author":"Udompap","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cjca.2025.06.075_bib12","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.14309\/ajg.0000000000001292","article-title":"Trends in the economic burden of chronic liver diseases and cirrhosis in the United States: 1996-2016","volume":"116","author":"Ma","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cjca.2025.06.075_bib13","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.54707","article-title":"Estimated burden of metabolic dysfunction-associated steatotic liver disease in US adults, 2020 to 2050","volume":"8","author":"Le","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.cjca.2025.06.075_bib14","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1002\/hep.32032","article-title":"NAFLD and alcohol-associated liver disease will be responsible for almost all new diagnoses of cirrhosis in Canada by 2040","volume":"74","author":"Flemming","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.cjca.2025.06.075_bib15","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1111\/liv.16022","article-title":"Material deprivation is associated with liver stiffness and liver-related outcomes in people with HIV","volume":"44","author":"Long","year":"2024","journal-title":"Liver Int"},{"key":"10.1016\/j.cjca.2025.06.075_bib16","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1136\/gutjnl-2023-330595","article-title":"MASLD: a systemic metabolic disorder with cardiovascular and malignant complications","volume":"73","author":"Targher","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.cjca.2025.06.075_bib17","doi-asserted-by":"crossref","DOI":"10.1093\/eurjpc\/zwae306","article-title":"Cardiovascular disease and metabolic dysfunction-associated steatotic liver disease: pathophysiology and diagnostic aspects","author":"M\u00f8ller","year":"2025","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.cjca.2025.06.075_bib18","article-title":"Impact of metabolic dysfunction-associated steatotic liver disease on cardiovascular structure, function, and the risk of heart failure","author":"Bansal","year":"2025","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2025.06.075_bib19","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S2468-1253(21)00308-3","article-title":"Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis","volume":"6","author":"Mantovani","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cjca.2025.06.075_bib20","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1136\/gutjnl-2020-322786","article-title":"Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort","volume":"70","author":"Simon","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.cjca.2025.06.075_bib21","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1136\/gutjnl-2020-320622","article-title":"NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications","volume":"69","author":"Targher","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.cjca.2025.06.075_bib22","article-title":"Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults","volume":"367","author":"Alexander","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.cjca.2025.06.075_bib23","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/HEP.0000000000000329","article-title":"Lean individuals with NAFLD have more severe liver disease and poorer clinical outcomes (NASH-CO Study)","volume":"78","author":"Nabi","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.cjca.2025.06.075_bib24","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1186\/s12933-024-02434-5","article-title":"Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review","volume":"23","author":"Zheng","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.cjca.2025.06.075_bib25","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1161\/ATVBAHA.122.318661","article-title":"Comparative associations of nonalcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease with coronary artery calcification: a cross-sectional and longitudinal cohort study","volume":"43","author":"Sung","year":"2023","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cjca.2025.06.075_bib26","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.atherosclerosis.2015.02.011","article-title":"The association of nonalcoholic fatty liver disease, obesity, and metabolic syndrome, with systemic inflammation and subclinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis (MESA)","volume":"239","author":"Al Rifai","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cjca.2025.06.075_bib27","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jhep.2015.02.045","article-title":"Hepatic steatosis and cardiovascular disease outcomes: an analysis of the Framingham Heart Study","volume":"63","author":"Mellinger","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.cjca.2025.06.075_bib28","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1161\/CIRCULATIONAHA.124.070535","article-title":"Cardiovascular-liver-metabolic health: recommendations in screening, diagnosis, and management of metabolic dysfunction-associated steatotic liver disease in cardiovascular disease via modified Delphi approach","volume":"151","author":"Chew","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2025.06.075_bib29","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2337\/dci24-0094","article-title":"Metabolic dysfunction-associated steatotic liver disease (MASLD) in people with diabetes: the need for screening and early intervention. A consensus report of the American Diabetes Association","volume":"48","author":"Cusi","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cjca.2025.06.075_bib30","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J Hepatol"},{"issue":"suppl 1","key":"10.1016\/j.cjca.2025.06.075_bib31","first-page":"S59","article-title":"4. Comprehensive medical evaluation and assessment of comorbidities: standards of care in diabetes---2025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cjca.2025.06.075_bib32","article-title":"Cardiovascular risk from metabolic dysfunction-associated steatotic liver disease, cardiometabolic risk factor count, and their longitudinal changes: a nationwide cohort study. Preprint","author":"Lee","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cjca.2025.06.075_bib33","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1007\/s10620-025-08893-4","article-title":"Advanced liver fibrosis impairs cardiorespiratory fitness in patients with metabolic dysfunction-associated steatotic liver disease","volume":"70","author":"Sogbe","year":"2025","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cjca.2025.06.075_bib34","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41569-021-00611-7","article-title":"The role of cardiac rehabilitation in improving cardiovascular outcomes","volume":"19","author":"Taylor","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.cjca.2025.06.075_bib35","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cjca.2025.06.075_bib36","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jhep.2015.02.022","article-title":"Effect of aerobic exercise training dose on liver fat and visceral adiposity","volume":"63","author":"Keating","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.cjca.2025.06.075_bib37","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/MEG.0000000000002887","article-title":"The impact of resistance training in patients diagnosed with metabolic dysfunction-associated steatotic liver disease: a systematic review","volume":"37","author":"Medeiros","year":"2025","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.cjca.2025.06.075_bib38","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1038\/ajg.2017.371","article-title":"Adherence to Mediterranean diet and non-alcoholic fatty liver disease: effect on insulin resistance","volume":"112","author":"Baratta","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cjca.2025.06.075_bib39","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJMoa1200303","article-title":"Primary prevention of cardiovascular disease with a Mediterranean diet","volume":"368","author":"Estruch","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2025.06.075_bib40","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jhep.2019.04.013","article-title":"The beneficial effects of Mediterranean diet over low-fat diet may be mediated by decreasing hepatic fat content","volume":"71","author":"Gepner","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.cjca.2025.06.075_bib41","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.3390\/nu16234225","article-title":"Healthy lifestyle changes improve cortisol levels and liver steatosis in MASLD patients: results from a randomized clinical trial","volume":"16","author":"Bagnato","year":"2024","journal-title":"Nutrients"},{"key":"10.1016\/j.cjca.2025.06.075_bib42","doi-asserted-by":"crossref","first-page":"4208","DOI":"10.3390\/nu16234208","article-title":"Inappropriate diet exacerbates metabolic dysfunction-associated steatotic liver disease via abdominal obesity","volume":"16","author":"Xiang","year":"2024","journal-title":"Nutrients"},{"key":"10.1016\/j.cjca.2025.06.075_bib43","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.14309\/ajg.0000000000001229","article-title":"Red meat consumption and risk of nonalcoholic fatty liver disease in a population with low meat consumption: the Golestan Cohort Study","volume":"116","author":"Hashemian","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cjca.2025.06.075_bib44","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.3390\/ijerph16122192","article-title":"Consumption of sugar-sweetened beverages has a dose-dependent effect on the risk of non-alcoholic fatty liver disease: an updated systematic review and dose-response meta-analysis","volume":"16","author":"Chen","year":"2019","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.cjca.2025.06.075_bib45","doi-asserted-by":"crossref","first-page":"e227","DOI":"10.1161\/ATVBAHA.124.321214","article-title":"Leisure sedentary behavior, physical activities, and cardiovascular disease among individuals with metabolic dysfunction-associated fatty liver disease","volume":"44","author":"Wu","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cjca.2025.06.075_bib46","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1080\/17474124.2024.2385487","article-title":"Integrating behavioral interventions into a holistic approach to metabolic dysfunction-associated steatotic liver disease","volume":"18","author":"Righetti","year":"2024","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cjca.2025.06.075_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2024.117523","article-title":"Metabolic dysfunction-associated steatotic liver disease: an opportunity for collaboration between cardiology and hepatology","volume":"392","author":"Raggi","year":"2024","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cjca.2025.06.075_bib48","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3390\/biom15030324","article-title":"Linking cardiovascular disease and metabolic dysfunction-associated steatotic liver disease (MASLD): the role of cardiometabolic drugs in MASLD treatment","volume":"15","author":"Zisis","year":"2025","journal-title":"Biomolecules"},{"key":"10.1016\/j.cjca.2025.06.075_bib49","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.cgh.2024.01.032","article-title":"The emerging role of glucagon-like peptide-1 receptor agonists for the treatment of metabolic dysfunction-associated steatohepatitis","volume":"22","author":"Abushamat","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cjca.2025.06.075_bib50","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2025.06.075_bib51","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa2401755","article-title":"A phase 2 randomized trial of survodutide in MASH and fibrosis","volume":"391","author":"Sanyal","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2025.06.075_bib52","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2025.06.075_bib53","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2025.06.075_bib54","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1080\/14656566.2024.2374463","article-title":"Pharmacotherapeutic options for metabolic dysfunction-associated steatotic liver disease: where are we today?","volume":"25","author":"Puengel","year":"2024","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.cjca.2025.06.075_bib55","article-title":"Efficacy of SGLT2 inhibitors versus pioglitazone in the treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis: a systematic review","volume":"15","author":"Kaur","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.cjca.2025.06.075_bib56","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/abr.abr_354_21","article-title":"Effect of pioglitazone on nonalcoholic fatty liver disease in morbid obese patients; a randomized controlled trial","volume":"12","author":"Sayadishahraki","year":"2023","journal-title":"Adv Biomed Res"},{"key":"10.1016\/j.cjca.2025.06.075_bib57","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMoa2304286","article-title":"Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH","volume":"389","author":"Loomba","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2025.06.075_bib58","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1038\/s41467-024-47919-9","article-title":"The pan-PPAR agonist lanifibranor improves cardiometabolic health in patients with metabolic dysfunction-associated steatohepatitis","volume":"15","author":"Cooreman","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.cjca.2025.06.075_bib59","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.cjco.2024.07.018","article-title":"Cardiac rehabilitation for prediabetes and metabolic syndrome remission: impact of ultraprocessed food-intake reduction and time-restricted eating in the DIABEPIC-1 study","volume":"6","author":"Iglesies-Grau","year":"2024","journal-title":"CJC Open"},{"key":"10.1016\/j.cjca.2025.06.075_bib60","doi-asserted-by":"crossref","first-page":"6212","DOI":"10.1038\/s41598-024-51470-4","article-title":"Effect of different exercise modalities on nonalcoholic fatty liver disease: a systematic review and network meta-analysis","volume":"14","author":"Xue","year":"2024","journal-title":"Sci Rep"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X2500532X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X2500532X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T23:25:13Z","timestamp":1780961113000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X2500532X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":60,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0828282X2500532X"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2025.06.075","relation":{},"ISSN":["0828-282X"],"issn-type":[{"value":"0828-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Integrating the Care of Metabolic Dysfunction\u2013associated Steatotic Liver Disease Into Cardiac Rehabilitation: A Multisystem Approach","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjca.2025.06.075","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of the Canadian Cardiovascular Society.","name":"copyright","label":"Copyright"}]}}